Search
GOA Therapeutics
GOA Therapeutics develops novel, dual-action enzymatic biologics designed to rapidly reverse acute alcohol intoxication and poisoning in emergency care settings. Its lead candidate, GOA26, is a two-stage injectable therapy engineered to accelerate ethanol clearance while sequestering toxic acetaldehyde byproducts—reducing blood alcohol concentrations by over 60% within 20 minutes in preclinical models. Addressing a critical gap where no FDA-...
Source of information:
goathera.com
Add to My List
Key Executives
Andrew Altschuler, CPA
Co-Founder, President, CEO & Chairman
Tami Ehrmann Barr, MD, PhD
Co-Founder & Chief Scientific Officer
Dean Hakanson, MD
Chief Medical Officer
Industries